U.S. Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews
This article was originally published in The Rose Sheet
The Public Access to SunScreens Coalition will recommend a user-fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.
You may also be interested in...
Addressing industry stakeholders as a member of a CHPA conference panel, FDA’s OTC monograph division chief Scott Furness says the agency shares companies’ frustration with the sluggish pace of monograph finalization. However, he shares some good news on time and extent applications.
A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.